secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2026-06-08T20:05:15+00:00
Accession:  0001193125-26-261696
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics shareholders approve doubling of authorized shares to 400M
----------------------------------------------------------------------------

- Shareholders elected David Lubner, Brian Posner, Jason Rhodes as Class III directors to three-year terms.
- Non-binding advisory vote approved executive compensation with ~98% of votes cast in favor.
- Authorized common stock doubled from 200M to 400M shares via charter amendment filed June 8.
- Charter amended to include officer exculpation provision limiting personal liability.
- Deloitte & Touche ratified as independent auditor for fiscal year ending December 31, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312526261696/0001193125-26-261696-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312526261696/dyn-20260605.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-261696

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer